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Abstract
Patients with severe chronic obstructive pulmonary disease (COPD) are at higher risk of developing invasive pulmonary aspergillosis
(IPA). However, there are limited data for this disease. To evaluate risk factors and the clinical characteristics of IPA in COPD patients,
we conducted a hospital-based, retrospective case-control study of 30 COPD patients with IPA and 60 COPD control patients without
IPA. Patients in the case group were significantly more likely to have concurrent co-morbidities than controls. Of the IPA patients,
65.4% had worsening radiological findings vs. 11.4% in the control group (p <0.001). IPA in COPD was associated with a higher propor-
tion of mechanical ventilation (43.3% vs. 5%; p <0.001), a longer hospital stay duration (45.8 ± 39.1 days vs. 18.4 ± 11.8 days; p <0.001),
and higher mortality (43.3% vs. 11.4%; p <0.001). Systemic use of steroids in the stable phase, treatment with three or more antibiotics
during hospitalization and antibiotic treatment longer than 10 days were independent risk factors associated with IPA. COPD patients
with obvious dyspnoea, antibiotic-resistant lower respiratory tract infection and repeated detection of Aspergillus in sputum should be
considered for the possibility of IPA.
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Introduction
Invasive pulmonary aspergillosis (IPA) is a life-threatening
pneumonia characterized by lung parenchyma invasion with
vasculature erosion and necrosis that is caused by oppor-
tunistic fungi belonging to the species Aspergillus. There is
growing evidence to suggest that the incidence of IPA in
the context of chronic obstructive pulmonary disease
(COPD) is increasing [1–3]. However, the clinical charac-
teristics, risk factors and pathogenesis of this disease are
limited, as most of the relevant data have come from
case/series reports. Here, we investigated the clinical con-
ditions and risk factors of IPA in COPD patients using a
case-control study that compared COPD patients with and
without IPA.
Materials and Methods
Study population and case definitions
This retrospective study enrolled 992 patients in the 2000-
bed Guangzhou General Hospital of Guangzhou Military
Command, Guangzhou, China, from January 2006 to Decem-
ber 2009. Ethics committee approval and patient consent
statements were waived due to the retrospective design.
A diagnosis of COPD was based on the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guidelines
[4]. The diagnostic criteria for IPA in COPD patients sug-
gested by Bulpa et al. [5] were used as a modified reference
in this study, and IPA in COPD patients was carefully moni-
tored in our hospital. Proven cases required histopathologi-
cal or cytopathological confirmation. Probable cases required
both host factors (COPD patient, had recent exacerbation
of dyspnoea and suggestive chest imaging, and typically had
poor response to conventional treatment) and microbiologi-
cal factors (isolation of Aspergillus in the lower respiratory
track (LRT) samples, or two consecutive positive serum
galactomannan (GM) tests). Possible cases required host
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE MYCOLOGY
factors, but without microbiological proof. Colonization was
defined as asymptomatic and isolation of Aspergillus in LRT
samples. Possible patients were excluded from this study.
Because we could not guarantee that all the patients had a
chest X-ray every 3 months, we only compared chest imag-
ing with the final results before admission for some patients.
We did not restrict patients to those with COPD stage III
or IV.
Inclusion and exclusion criteria
Case group patients were admitted to the hospital with an
initial diagnosis of acute exacerbations of COPD
(AECOPD), and were diagnosed as ‘probable IPA’ after
relevant examinations. Control group patients met the fol-
lowing conditions: (i) had a primary discharge diagnosis of
COPD (International Classification of Diseases, tenth revi-
sion (ICD-10) codes J44.0, J44.1, J44.9); (ii) had exacerba-
tions of baseline symptoms of COPD, such as dyspnoea,
cough and/or sputum, at admission; (iii) had an aetiology
examination with LRT samples more than twice and Asper-
gillus was negative; and (iv) did not receive any antifungal
therapy during hospital stay. Patients were excluded for:
(i) concurrent malignant tumour; (ii) concurrent haemato-
logical system diseases; (iii) organ transplantation; (iv)
apparent immunodeficiency (e.g. AIDS or immunosuppres-
sive drugs); and (v) long-term use of glucocorticoid for
reasons other than COPD.
Laboratory procedures
A sputum sample with >25 polymorphonuclear leukocytes
and <10 squamous epithelial cells per low-power field was
defined as a valid sputum sample representative of the
lower airways. All samples were cultured on conventional
media, including blood agar, chocolate agar, MacConkey
agar and Sabouraud’s Dextrose agar. Bacterial infection
was defined as a colony count ‡105 cfu/mL. Aspergillus iso-
lates were identified using microculture and standard mor-
phological procedures. GM antigen levels in serum were
determined with Platelia GM-EIA kits (Bio-Rad, Marnes-
la-Coquette, France). A cut-off of index ‡1 was used to
define a positive result.
Data collection
Electronic medical records of all the cases were searched
from our medical records centre. Variables included demo-
graphic factors, body mass index (BMI), smoking history, co-
morbidities, pulmonary function, medication history, clinical
manifestations, laboratory test results, imaging findings,
mechanical ventilation, antibiotics and steroid therapy, length
of hospital stay, and outcome.
Statistical analysis
Results were given as means ± SDs or number of positive
results. Categorical variables were compared using chi-
square or Fisher’s exact tests; continuous variables were
compared using t-test or the Mann-Whitney U-test. Multivar-
iate logistic regression was performed in a stepwise manner
to search for risk factors associated with IPA in COPD
patients. Variables with a level of significance <0.2 in the uni-
variate analysis were included in the model. The level of sig-
nificance was set at 0.05. Statistical analysis used SPSS,
version 11.5.
Results
Patients
Our hospital had 992 AECOPD admissions, of which 298
(30.0%) had LRT sample examinations at least twice.
Amongst these, 58 had isolates of Aspergillus from LRT sam-
ples, with 19 cases diagnosed as colonization according to
the criteria described in ‘Materials and methods’. Thirty-nine
(3.9%) were diagnosed with IPA, but only 30 were included
in the case group. Excluded cases had other concurrent con-
ditions: four had malignant tumours; two had haematological
system diseases; and three used immunosuppressive drugs
for rheumatoid arthritis. We were not able to perform biop-
sies, so all cases were classified as probable IPA. Of the 240
patients with Aspergillus-negative LRT samples, 15 had
received antifungal therapy, 11 had concurrent tumours, two
had concurrent haematological system diseases, and six used
glucocorticoids for a long time for reasons other than
COPD. Of the remaining 206 patients, we randomly selected
60 cases as the control group.
In the case group, 29 were identified as having Aspergillus
fumigatus, and one had Aspergillus flavus. GM testing was per-
formed only for serum: 16 cases had the test once and six
of these were positive; three cases had the test at least
twice and all results were positive. The GM antigen positive
rate in the case group was 47.4%. IPA was diagnosed within
5–30 days. The average diagnosis time was 11.5 ± 5.1 days
for those who survived and 15.0 ± 8.1 days for those who
died (p 0.19).
Baseline characteristics
Cases and controls did not differ significantly regarding sex,
age, BMI or smoking history. Based on the GOLD criteria
for COPD severity, 83.3% of the case group patients had
stage III or IV disease, which was higher than in the control
group (68.3%), although not significantly different (p 0.13).
Co-morbidities were more common in the case group.
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Pre-hospital treatments for the two groups were also signifi-
cantly different, particularly the use of broad-spectrum antibi-
otics during the previous 3 months (83.3% in the case group
vs. 30% in the control group; p <0.001; Table 1).
Clinical characteristics
The main clinical manifestations and treatments are shown in
Table 2. Dyspnoea was the most common complaint of IPA
patients (93.3%), and 80% experienced wheezing. Radiological
signs for each group are listed in Table 2. The proportions
with initial abnormal imaging findings in the two groups were
not significantly different (p 0.64 for chest X-rays, p 0.92 for
computerized tomography (CT) scans). However, for
dynamic observations, 65.4% of the IPA patients had pro-
gressing lung lesions, while only 11.4% in the control group
had these features (p <0.001).
The detection rates for other pathogens (e.g. Acinetobacter
baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa,
Stenotrophomonas maltophilia, Staphylococcus aureus, and oth-
ers) were significantly different between the two groups
(70% vs. 31.7%; p 0.001).All case group patients were treated
with broad-spectrum antibiotics, and 73.3% had received
three or more kinds of antibodies compared with 8.3% in
the control group (p <0.001).
The proportions receiving inhaled corticosteroid treat-
ments were not significantly different between the groups.
However, a significantly higher proportion of systemic corti-
costeroid use was observed in the case group (66.7% vs.
40%; p 0.017); further, more than one-quarter of IPA cases
were treated with an accumulated steroid dose of >700 mg
prednisone or its equivalent (26.7% vs. 3.3%; p 0.002).
The results of biological variables in the two groups are
shown in Table 3. Although no significant differences were
found between the groups in blood gas analysis, the propor-
tion with hypoxemia in the case group was still higher, and
nearly half of these IPA cases received mechanical ventilation
(43.3% vs. 5%; p <0.001); only one of them survived.
Multivariate logistic regression analysis
Variables with a p-value <0.2 in the univariate analyses were
included in logistic regression analysis. These results are
shown in Table 4. Use of systemic steroids before admission,
treatment with three or more antibiotics during hospitaliza-
tion and duration of antibiotic treatment longer than
10 days, were independent risk factors associated with IPA.
TABLE 1. Baseline characteristics of patients with and with-
out invasive pulmonary aspergillosisa
Characteristics
IPA
group
(n = 30)
Control
group
(n = 60) p
Total 30 60
Male 25 (83.3) 53 (88.3) 0.51
Female 5 (16.7) 7 (11.7)
Age, years 77.2 ± 7.2 76.4 ± 8.3 0.65
BMI, kg/m2 21.6 ± 2.8 21.1 ± 3.5 0.51
Smoking history
Yes 23 (76.7) 42 (70.0) 0.51
>40, pack years 12 (40.0) 20 (33.3) 0.53
Co-morbidities
Diabetes mellitus 9 (30.0) 4 (6.7) 0.008
Cardiovascular diseasesb 25 (83.3) 36 (60.0) 0.026
Chronic renal insufficiencyc 4 (13.3) 1 (1.7) 0.041
Pulmonary function stage
GOLD stage III or IV 25 (83.3) 41 (68.3) 0.13
FEV1% 36.9 ± 15.4 41.5 ± 16.8 0.21
Steroid treatment
Inhaled 15 (50.0) 16 (26.7) 0.028
Systemic use 4 (13.3) 2 (3.3) 0.093
Recent use of antibioticsd 25 (83.3) 18 (30.0) <0.001
BMI, body mass index; FEV1, forced expiratory volume in 1 s.
aData are presented as mean ± SD or No. (%).
bPrimary hypertension, coronary atherosclerotic heart disease and chronic heart
insufficiency were included.
cCreatinine >133 lM.
dIn the 3 months prior to admission.
TABLE 2. Clinical characteristics of patients with and with-
out invasive pulmonary aspergillosisa
Characteristics
IPA
group
(n = 30)
Control
group
(n = 60) p
Clinical signsb
Fever (>38C) 3 (10.0) 14 (23.3) 0.16
Dyspnoea 28 (93.3) 38 (63.3) 0.002
Sputum increase 12 (40.0) 43 (71.7) 0.004
Wheezing 24 (80.0) 35 (58.3) 0.041
Radiological data
Chest radiograph abnormalc 0.64
Infiltrates 9 (34.6)d 9 (25.7)e
Nodules 3 (11.5)d 1 (2.9)e
Cavitations 1 (3.8)d 0 (0)e
Consolidations 2 (7.7)d 2 (5.7)e
CT scan abnormal 0.92
Halo sign 1 (5.9)f 0g
Infiltrates 12 (70.6)f 8 (53.3)g
Nodules 4 (23.5)f 2 (13.3)g
Cavitations 3 (17.6)f 1 (6.7)g
Consolidations 3 (17.6)f 2 (13.3)g
Worsening radiological signh 17 (65.4)d 4 (11.4)e <0.001
Other pathogens positive 21 (70.0) 19 (31.7) 0.001
Mechanical ventilation 13 (43.3) 3 (5.0) <0.001
Antibiotic treatment
Three or more kinds 22 (73.3) 5 (8.3) <0.001
Duration >10 days 27 (90.0) 29 (48.3) <0.001
Carbapenemi 13 (43.3) 6 (10.0) <0.001
Steroid treatment
Inhaled 21 (70.0) 32 (53.3) 0.13
Systemic use 20 (66.7) 24 (40.0) 0.017
>700 mg 8 (26.7) 2 (3.3) 0.002
Hospital stay 45.8 ± 39.1 18.4 ± 11.8 <0.001
Mortality in hospital 13 (43.3) 4 (11.4) <0.001
CT, computed tomography.
aData are presented as mean ± SD or No. (%).
bThe clinical features were considered at hospital admission.
cThe first chest radiograph results were included.
dn = 26 (only 26 cases had chest radiograph examination in the case group).
en = 35 (only 35 cases had chest radiograph examination in the control group).
fn = 17 (only 17 cases had a CT scan).
gn = 15 (only 15 cases had a CT scan).
hNew images of infection appeared or old lesions worsened in comparison with
previous chest radiographs.
iCarbapenem medicines included Imipenem and cilastatin, Meropenem, and Er-
tapenem.
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In addition, recent use of antibiotics and the pulmonary func-
tion stage had an interactive effect in this model. Broad-spec-
trum antibiotics during the 3 months prior to admission
significantly increased the probability of IPA in patients with
GOLD stage III or IV (Table 5).
Antifungal treatments and outcomes
In the case group, 26 patients had antifungal treatments: vo-
riconazole (13); caspofungin (6); itraconazole (6); and vorico-
nazole combined with caspofungin (1). Among these, nine
cases died during their hospital stay. In addition, four sub-
jects in the case group who declined antifungal therapy also
died. We followed-up 17 survivors for 6 months; three died
of AECOPD during this period.
Discussion
This study showed that COPD patients with concurrent IPA
are more likely to be in a critical condition. Compared with
non-IPA patients, COPD patients with concurrent IPA had a
higher proportion receiving mechanical ventilation, longer
hospital stays, and higher mortality.
Aspergillosis in patients without classical predisposing fac-
tors has been consistently reported [6–9]. A multicentre
prospective study showed that COPD was one of most
important predisposing factors for Aspergillus spp. coloniza-
tion/infection in critically ill patients [10]. However, the fre-
quency of IPA in COPD patients has been poorly
documented. In one large study, Guinea et al. [11] reported
that 1.63% of COPD admissions had isolates of Aspergillus
from their LRT samples and, of these, 22.1% had probable
IPA. In our study, the incidence of COPD complicated with
Aspergillosis was 3.9%, which was significantly higher than in
other reports [12–14]. This discrepancy may be due, at least
partially, to different diagnostic criteria used, regional cli-
mates, living conditions, and racial differences.
There are no standard diagnostic criteria for IPA in
COPD patients. In 2007, Bulpa et al. [5] proposed definitions
of IPA in COPD. By these definitions, in terms of classifica-
tion criteria, patients must have COPD classified as GOLD
stage III or IV. Because there are no indications that IPA
does not occur in moderately severe COPD patients, it
seems inappropriate to exclude those patients only because
their lung function does not meet the criteria. In our case
group, five patients were GOLD stage II. They were all trea-
ted with systemic steroids during hospitalization and three of
them had received inhaled corticosteroids in the stable phase
(although this was inappropriate). Because of repeated detec-
tions of Aspergillus in sputum and antibiotic-resistant lower
respiratory tract infections in these patients, the diagnosis of
IPA was approved by clinicians, even without biopsies. Anti-
fungal treatments were selected and the patients’ clinical
conditions improved.
Previous studies have suggested that COPD patients with
IPA have poor lung function [2]. However, the relationship
between pulmonary function classification and Aspergillus sus-
ceptibility remains unclear. In this study, there was no signifi-
cant difference in the proportions of patients with GOLD
TABLE 3. Biological parameters of the two groups at
admissiona
Parameters
IPA
group
(n = 30)
Control
group
(n = 60) p
Leucocyte count, 103/mL 11.7 ± 7.7 9.1 ± 4.1 0.19
Eosinophil count, cells/mL 189 ± 201 148 ± 175 0.32
Haemoglobin, g/dL 12.6 ± 2.1 13.7 ± 1.9 0.015
Platelets, 103/mL 194.9 ± 75.5 201.7 ± 82.3 0.71
Albumin, g/dL 38.8 ± 9.4 38.0 ± 3.5 0.99
Urea nitrogen, mM 7.9 ± 4.4 5.8 ± 2.4 0.016
Creatinine, lM 107.6 ± 100.1 76.9 ± 22.8 0.17
Blood gas analysis
PaO2 < 60 mmHg 15 (57.7)
b 16 (36.4)c 0.083
PaCO2 > 45 mmHg 16 (61.5)
b 25 (56.8)c 0.70
SaO2 < 90% 14 (53.8)
b 14 (31.8)c 0.069
aData are presented as mean ± SD or No. (%).
bn = 26 (only 26 cases had a blood gas test in the case group).
cn = 44 (only 44 cases had a blood gas test in the control group).
TABLE 4. Multivariate logistic regression analysis of risk fac-
tors for invasive pulmonary aspergillosis in patients with
chronic obstructive pulmonary disease
Variable Wald OR 95% CI p
Systemic use of steroids
in stable phase
6.592 37.84 2.36–606.98 0.01
Three or more kinds
of antibioticsa
16.297 46.90 7.24–303.78 0.000
Duration of antibiotic
use >10 daysa
5.763 13.41 1.61–111.72 0.016
Pulmonary function stage*
Recent use of antibioticsb
10.649 20.26 3.33–123.47 0.001
aDuring admission.
bIn the 3 months prior to admission.
TABLE 5. Interaction of pulmonary function stage and
recent use of antibiotics in multivariate modela
IPA
Pulmonary function stage I or
II
Pulmonary function stage III
or IV
Without
antibioticsb
With
antibioticsc Total
Without
antibioticsb
With
antibioticsc Total
No 11 (84.6) 8 (72.7) 19 31 (91.2) 10 (31.3) 41
Yes 2 (15.4) 3 (27.3) 5 3 (8.8) 22 (68.8) 25
Total 13 11 24 34 32 66
IPA, invasive pulmonary aspergillosis.
aData are presented as No. (%).
bWithout use of antibiotics in the 3 months prior to admission.
cUse of antibiotics in the 3 months prior to admission.
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stage III or IV in the two groups. However, in the multivari-
ate model, the lung function stage and recent use of antibiot-
ics showed an interactive effect. The risk of IPA increased 20
times in patients with poor lung function when recently trea-
ted with antibiotics (OR 20.26). We suspect that this may
indicate more cases of colonization of Aspergillus in severe
COPD patients.
Steroids are believed to play a role in the emergence of
IPA in COPD patients [2,5]. Guinea et al. [11] reported that
the accumulated doses of corticosteroids (>700 mg) received
during the 3 months prior to admission significantly
increased the risk of IPA in COPD patients. Some reports
suggested that high doses of inhaled corticosteroids might
also be a risk factor for IPA [15,16]. In this study, the case
group had a higher proportion of inhaled steroid use while
stable. However, data on the timing and dose of inhaled cor-
ticosteroids were not complete for this study. During their
hospital stay, the case group had more systemic use of corti-
costeroids and higher doses, which might have been related
to serious dyspnoea symptoms. However, high-dose systemic
steroid use might promote Aspergillus airway colonization to
develop into IPA.
Co-morbidities were more common in the case group,
suggesting that COPD patients with underlying diseases may
be more susceptible to Aspergillus. An underlying disease
might also be partly responsible for more severe clinical con-
ditions. Another prominent feature was that the case group
had a higher detection rate for other pathogens and more
types of pathogens in their sputum samples than the control
group, suggesting that mixed infections are very common in
COPD with IPA. Perhaps due to these many reasons, the
administration of antibiotics in the case group was signifi-
cantly increased.
The mortality rate of IPA in COPD patients is very high
[5,11,17]. Thus, a prompt diagnosis and treatment are impor-
tant for improving the outcomes. However, early diagnosis
of IPA is always a problem clinically. A CT scan and a serum
GM antigen test are the most common methods for an early
diagnosis of IPA in immunocompromised hosts. However,
typical CT scan features, such as consolidation, ‘air-crescent
sign’ and ‘halo sign’, are very rare in COPD patients with
IPA [2,5,11]. In recent years, nearly all studies that included
serum GM antigen tests were limited to immunocompro-
mised hosts. For immunocompetent patients, the positive
rate for GM antigen is under 50%, as the GM antigen is sus-
ceptible to macrophage clearance [11,18]; this rate is much
lower than in immunocompromised hosts (61–71%) [19].
Our report had a similar result (47.4%). Because most of the
positive patients had the GM test only once, false-positive
results caused by the use of piperacillin-tazobactam and
amoxicillin-clavulanate could not be avoided. Therefore, the
real positive rate might be lower.
For the retrospective study, bias in the design itself is diffi-
cult to avoid. We cannot ask all patients to have sputum
examinations at the same time and under similar conditions.
Clinicians decide whether or not patients need sputum fungal
cultures. Those patients who have no apparent indications of
fungal infection would not have sputum fungal cultures.
Therefore, this study cannot fully account for positive Asper-
gillus cultures in COPD. However, because this study
depended on searching for Aspergillus in LRT samples, no
proven patient was included in the case group, so the real
incidence of IPA in COPD patients could not be determined.
The relationship between the use of antibiotics and IPA
remains confusing. Although treatment with multiple antibiot-
ics and a longer duration of antibiotic treatment were inde-
pendent risk factors associated with IPA, it remains difficult
with the present data to strongly affirm that these are not
just indicators of disease severity.
In summary, COPD patients with IPA are in a very critical
condition. A prompt diagnosis is important in order to pro-
vide the maximum chance of successful treatment. Dyspnoea
and antibiotic-resistant pneumonia are the most prominent
clinical manifestations. In this context, positive Aspergillus cul-
ture from LRT samples should be regarded as an important
clue of infection.
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